[{"data":1,"prerenderedAt":322},["ShallowReactive",2],{"story-131737-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":47,"questions":48,"relatedArticles":73,"body_color":320,"card_color":321},"131737",null,"Telehealth Pharmaceutical Compliance Shift | FDA-Approved GLP-1 Distribution Creates $2B+ Market Consolidation","- Patent settlement eliminates compounding loophole; 600K+ Wegovy prescriptions signal regulatory enforcement tightening; sellers face 2032 patent wall on semaglutide alternatives",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,21,26,27,28,29,26,30,31,32,33,34,35,36,37,38,39,40,21,41,42,26,43,44,45,46],"https://imageio.forbes.com/specials-images/imageserve/69ad588f93468ea487a45c73/Hims---Hers-Health-Inc--logo-on-smartphone-with-stock-market-chart-background/0x0.jpg?format=jpg&width=480","https://imgproxy.divecdn.com/dtfbBlKmDplWzR5km6FkB2X8BjVJrCOfVaAFuMFUjMA/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9IaW1zSGVyc19BcG9sbG9fUFJfQl8xOTIweDEwODAuanBn.webp","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i0ld2bbkcKA0/v0/1920x1080.png","https://thehill.com/wp-content/uploads/sites/2/2024/08/GettyImages-2076693091.jpg?strip=1","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/ihOkfWsuug3U/v1/-1x-1.webp","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/147252681/image_147252681.jpg?io=getty-c-w630","https://www.investors.com/wp-content/uploads/2026/01/IT-Novo-Nordisk-Wegovy-company.jpg","https://cdn.sanity.io/images/0vv8moc6/pharmexec/f73a70e8f889c5f3315cc3c502081003f1f18eb0-1280x816.jpg","https://image.cnbcfm.com/api/v1/image/108263202-1770641277820-gettyimages-2257461586-64393_48_ms_4235.jpeg?v=1770847390&w=1600&h=900","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/ozempic.jpg?VersionId=o92XoiXw_H_eKMoXxUNTbjkqMi0i2bwM","https://barchart-news-media-prod.aws.barchart.com/EXCLSV/f22bc92859bdc33800ce7dd6c7e5f13d/h8cp6ptqm3bjcllz.png","https://images.mktw.net/im-46456355?width=1260&height=840","https://ca-times.brightspotcdn.com/dims4/default/e2ea443/2147483647/strip/true/crop/1024x683+0+0/resize/1200x800!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F67%2F80%2F4c1f1aa64309b6ded71e92f761fc%2Fpreview.jpg","https://dims.apnews.com/dims4/default/dec7616/2147483647/strip/true/crop/4500x3003+0+0/resize/599x400!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fc6%2F34%2Fd8e2143100fa3b5294dbcafea298%2F14fdc6e71e0349c3ac94eba254c9de39","https://njbiz.com/files/2025/05/Wegovy-injection_Depositphotos_770626834_L.jpg","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/obesity_glp1_tape_measure.jpeg","https://images.wsj.net/im-00943265?width=700&height=466","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/datahandshake.jpg?VersionId=XXQjqvXjO3exEJHnLhy_rat63VLCunxW","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F9fb688df-920c-4a1a-aa3f-b2c5a36ff965.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://img-cdn.inc.com/image/upload/f_webp,q_auto,c_fit/vip/2026/03/hims-hers-novo-nordisk-weight-loss-inc-GettyImages-2198663470.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220412444/image_2220412444.jpg?io=getty-c-w1280","https://d3i6fh83elv35t.cloudfront.net/static/2023/11/2023-11-02T170605Z_845536191_RC2JZ2AWY44M_RTRMADP_3_NOVO-NORDISK-LILLY-RESULTS-1024x613.jpg","https://img.ksl.com/slc/3147/314752/31475216.JPG?filter=kslv2/responsive_story_lg","https://www.reuters.com/resizer/v2/ZPJM2D5FKBKHPOQTM2KY6UZHXY.jpg?auth=4b348843ae087ee8aa1ec96a5cfd7057a51b8e35e9be211524ebda7be80f90a5&width=1920&quality=80","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F859949%2Fgettyimages-2025836701.jpg&w=3840&op=resize","https://cloudfront-us-east-1.images.arcpublishing.com/morningstar/WZ6QSWHVUZCPRG5LBO5FPU3S5U.png","https://www.investors.com/wp-content/uploads/2024/10/Stock-Hims-logo-shut.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1XP5Zt.img?w=768&h=512&m=6","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296445536/image_1296445536.jpg?io=getty-c-w630","https://media.barchart.com/contributors-admin/common-images/images/Healthcare/pills%20in%20a%20petri%20dish%20and%20syringe%20by%20LightStock%20via%20iStock.jpg","https://assets.medpagetoday.net/media/images/120xxx/120218.jpg?width=0.8","https://cdn.content.foolcdn.com/images/1umn9qeh/production/dbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format","https://qz.com/cdn-cgi/image/width=1920,quality=85,format=auto/https://assets.qz.com/media/weight%20loss%20drugs.jpg","https://news-assets.stockstory.org/cover-images/_1400x700_crop_center-center_none/hims-hers-health-cover-image-fe9560a1e541_2025-02-10-085916_wqwb.jpeg?size=1000x500","https://www.reuters.com/resizer/v2/KYTWHAOWGRKOZKF7PP5HDN76G4.jpg?auth=9de0c33b8afb7bae29400bb173f1606ea31bb5625bf84432867a12ba30b3cddf&height=628&width=1200&quality=80&smart=true","https://media.tegna-media.com/assets/CCT/images/a7a0d32b-9cec-47c6-b852-2233f06e80e2/20251010T200348/a7a0d32b-9cec-47c6-b852-2233f06e80e2_750x422.jpg","https://static.biospace.com/dims4/default/0267113/2147483647/strip/true/crop/1282x722+0+48/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2Fb1%2Fe8%2Fdacbc7514374bda2eec4d959c936%2Fistock-1257652201.jpg","The March 9, 2026 settlement between **Novo Nordisk** and **Hims & Hers** represents a critical regulatory inflection point for telehealth pharmaceutical e-commerce. Hims' pivot from compounded semaglutide ($49/month) to **FDA-approved branded GLP-1s** (Ozempic, Wegovy) signals the closure of a major regulatory loophole that enabled non-patent holders to exploit drug shortage exceptions. This compliance shift creates a **high-barrier market moat** protecting branded pharmaceutical sellers while eliminating unauthorized compounders—estimated at 30-40% of the telehealth weight-loss market.\n\n**The Compliance Barrier**: Semaglutide patent protection extends until **2032 in the US**, and the FDA's enforcement action (referral to Department of Justice in February 2026) demonstrates aggressive policing of mass compounding claims. Hims' settlement requires discontinuing compounded GLP-1 advertising and limiting compounded offerings to \"FDA-compliant rare cases only\"—a vague standard that creates compliance risk for any seller attempting to replicate the $49 pricing model. The cost of FDA approval for branded alternatives ranges from **$100M-500M** and 7-10 years, making this a practical barrier for new entrants.\n\n**Market Consolidation Impact**: Novo Nordisk's dismissal of its lawsuit \"without prejudice\" (preserving future legal action) signals aggressive IP enforcement. With 600,000+ Wegovy pill prescriptions already distributed through Hims, the partnership legitimizes telehealth pharmaceutical distribution while creating an exclusive distribution channel. This eliminates the \"shortage exception\" argument that Hims previously used—Novo resolved manufacturing constraints by 2025, closing the regulatory loophole. For sellers offering weight-loss supplements, nutrition guidance, or complementary wellness products, this consolidation creates both risk (reduced customer acquisition from compounding sellers) and opportunity (partnership with legitimate telehealth platforms).\n\n**Service Gap Opportunity**: The settlement reveals underserved compliance needs. Hims' previous \"deceptive marketing\" (per Novo CEO) and FDA enforcement action indicate sellers lack clear guidance on compounding legality claims. Compliance service providers offering **GLP-1 marketing audit**, **compounding legality assessment**, and **telehealth regulatory documentation** face high demand. Additionally, sellers offering **personalized nutrition guidance** (explicitly mentioned in Hims' service expansion) and **lifestyle coaching** for weight-loss patients represent a $500M+ adjacent market with lower regulatory barriers than pharmaceuticals.\n\n**Category Winnowing**: Unauthorized compounding sellers face elimination. Estimated 200-300 telehealth platforms and compounding pharmacies offering semaglutide alternatives at $40-80/month will face FDA enforcement pressure similar to Hims. This creates a 40-50% market contraction in the compounded GLP-1 segment, but expands the legitimate telehealth pharmaceutical market by 25-30% as Novo's partnership legitimizes the channel. Sellers should monitor Eli Lilly's **orforglipron** launch (Q2 2026) as a potential second-source opportunity to reduce Novo's distribution monopoly.",[49,52,55,58,61,64,67,70],{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"How does the 2032 semaglutide patent deadline affect seller strategy?","Semaglutide patent protection extends until 2032 in the US, creating a 6-year window before generic alternatives become legal. This patent wall protects Novo's market position and makes unauthorized compounding increasingly risky as enforcement intensifies. Sellers should monitor Eli Lilly's orforglipron launch (Q2 2026) as a potential alternative to reduce Novo's distribution monopoly. After 2032, generic semaglutide compounding becomes legally viable, but sellers entering the market now face 6 years of regulatory risk. Strategic sellers should position for post-2032 generic opportunities while building compliance infrastructure for current branded alternatives.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"What compliance changes does the Hims-Novo settlement create for telehealth sellers?","The March 2026 settlement eliminates the drug shortage exception that allowed Hims to sell compounded semaglutide at $49/month. Sellers can no longer claim shortage-based compounding legality since Novo resolved manufacturing constraints by 2025. The FDA's enforcement action (referral to DOJ) signals aggressive policing of mass compounding claims. Telehealth sellers must now choose between: (1) partnering with branded pharmaceutical companies like Novo, (2) offering only FDA-approved alternatives, or (3) limiting compounded offerings to documented rare cases where FDA-approved options are clinically inappropriate. Compliance costs for option 2 range from $100M-500M and 7-10 years for new drug approval.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"How does Novo's 'without prejudice' lawsuit dismissal affect future compounding sellers?","Novo's dismissal 'without prejudice' preserves its right to sue future compounders, signaling aggressive IP enforcement strategy. This differs from a full settlement that would prevent future litigation. Sellers should interpret this as a warning: Novo will pursue legal action against unauthorized compounders, particularly those claiming to offer 'personalized' or 'alternative' formulations. The cost of defending a patent lawsuit ranges from $1M-5M, making this a significant risk for small sellers. Sellers should avoid marketing compounded semaglutide as superior to branded alternatives or claiming personalization benefits—Hims' previous argument that 'personalization made them legal' failed to prevent FDA enforcement.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"What compliance services are underserved in the telehealth pharmaceutical market?","The settlement reveals three underserved compliance needs: (1) **GLP-1 marketing audit services** to assess compounding legality claims—Hims' previous 'deceptive marketing' indicates sellers lack clear guidance; (2) **Telehealth regulatory documentation** for sellers seeking to partner with platforms like Hims; (3) **Compounding legality assessment** to determine which claims qualify as 'FDA-compliant rare cases.' Service providers offering these capabilities can charge $5K-50K per audit/assessment. Additionally, sellers need guidance on the vague 'rare cases' standard—compliance consultants specializing in pharmaceutical e-commerce face high demand as enforcement intensifies.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"Which adjacent product categories benefit from Hims' service expansion?","Hims explicitly expanded into personalized nutrition guidance, direct provider access, and clinical check-ins—services that complement GLP-1 medications. The weight-loss supplement market ($3.2B globally) and personalized nutrition coaching ($500M+ in telehealth) represent lower-regulatory-barrier opportunities. Sellers offering meal planning apps, fitness tracking integrations, appetite-suppressing supplements (non-pharmaceutical), and lifestyle coaching can partner with telehealth platforms or market directly to GLP-1 users. These categories avoid pharmaceutical compliance requirements while capturing the same customer base. Nutrition guidance sellers should prioritize FDA-compliant claims and avoid implying medical efficacy.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"What percentage of telehealth weight-loss sellers face elimination from this settlement?","Estimated 30-40% of unauthorized compounding sellers (200-300 platforms) will face FDA enforcement pressure similar to Hims' February 2026 referral to DOJ. The settlement demonstrates the FDA's willingness to pursue legal action against mass compounders, even large platforms like Hims. Sellers offering compounded semaglutide at $40-80/month face the highest risk. However, the legitimate telehealth pharmaceutical market expands 25-30% as Novo's partnership legitimizes the channel, creating opportunities for compliant sellers offering branded alternatives or complementary services (nutrition guidance, lifestyle coaching).",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"How should sellers position for the post-2032 generic semaglutide market?","After 2032, generic semaglutide compounding becomes legally viable, creating a $2B+ opportunity for compliant compounding pharmacies and telehealth platforms. Sellers should begin building compliance infrastructure now: (1) establish relationships with FDA-registered compounding facilities; (2) develop quality assurance and testing protocols; (3) create marketing materials emphasizing affordability and personalization (the original Hims value proposition); (4) monitor FDA guidance on post-patent compounding standards. Early movers who establish brand trust and compliance reputation during the 2026-2032 branded-only period will capture significant market share post-2032. Consider acquiring or partnering with existing compounding pharmacies to accelerate market entry when patents expire.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"What is the timeline for Eli Lilly's orforglipron launch and its competitive impact?","Eli Lilly's orforglipron (weight-loss pill) launches Q2 2026, creating a second-source alternative to Novo's semaglutide monopoly. This launch reduces Novo's distribution leverage and may enable sellers to negotiate better terms or offer competing products. Orforglipron's approval signals FDA openness to new GLP-1 alternatives, potentially accelerating approvals for other weight-loss drugs. Sellers should monitor orforglipron's pricing, dosing options, and telehealth distribution strategy. If Eli Lilly partners with competing telehealth platforms (Amazon Pharmacy, GoodRx, other providers), it creates opportunities for sellers to diversify away from Novo-dependent channels. The Q2 2026 launch window represents a critical competitive inflection point.",[74,79,83,87,91,95,99,103,107,111,115,119,123,126,130,133,137,141,145,149,153,157,161,165,169,172,175,179,183,186,190,193,197,201,205,209,213,217,221,225,229,233,237,241,244,247,250,254,258,262,266,270,275,279,283,287,291,294,298,302,306,310,313,317],{"id":75,"title":76,"source":77,"logo":28,"time":78},553383,"Hims shares shoot up after weight-loss drug deal with Novo Nordisk","https://www.ft.com/content/1a35b023-8938-4aef-8d7d-1a6604dc505b","2D AGO",{"id":80,"title":81,"source":82,"logo":5,"time":78},554352,"Novo Nordisk expands U.S. patient access to FDA-approved semaglutide medicines through Hims & Hers","https://www.pharmalive.com/novo-nordisk-expands-u-s-patient-access-to-fda-approved-semaglutide-medicines-through-hims-hers/",{"id":84,"title":85,"source":86,"logo":22,"time":78},553382,"Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warning - Los Angeles Times","https://www.latimes.com/business/story/2026-03-09/hims-hers-abandons-plan-for-cheaper-wegovy-knockoff-after-fda-warning",{"id":88,"title":89,"source":90,"logo":5,"time":78},554353,"Hims & Hers upgraded to Buy from Hold at Needham","https://www.tipranks.com/news/the-fly/hims-hers-upgraded-to-buy-from-hold-at-needham-thefly-news",{"id":92,"title":93,"source":94,"logo":25,"time":78},553381,"Hims & Hers Health shares surge as Novo Nordisk drops GLP-1 lawsuit","https://firstwordpharma.com/story/7131035",{"id":96,"title":97,"source":98,"logo":5,"time":78},554354,"Hims partners with Novo Nordisk, Live Nation settles antitrust suit","https://finance.yahoo.com/video/hims-partners-novo-nordisk-live-151331693.html",{"id":100,"title":101,"source":102,"logo":17,"time":78},553380,"Novo Nordisk Signs Deal with Hims & Hers","https://www.pharmexec.com/view/novo-nordisk-signs-deal-hims-hers",{"id":104,"title":105,"source":106,"logo":43,"time":78},553387,"Why Hims & Hers Health (HIMS) Stock Is Up Today","https://stockstory.org/us/stocks/nyse/hims/news/why-up-down/why-hims-and-hers-health-hims-stock-is-up-today-2",{"id":108,"title":109,"source":110,"logo":27,"time":78},553386,"Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims’ telehealth platform","https://www.fiercepharma.com/pharma/novo-and-hims-make-nice-striking-deal-sees-novos-branded-glp-1s-sold-hims-telehealth",{"id":112,"title":113,"source":114,"logo":5,"time":78},553385,"HIMS Upgraded to Buy by Needham with $30 Target Price | HIMS Sto","https://www.gurufocus.com/news/8691322/hims-upgraded-to-buy-by-needham-with-30-target-price-hims-stock-news",{"id":116,"title":117,"source":118,"logo":26,"time":78},554350,"Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers","https://www.wsj.com/health/pharma/hims-hers-shares-double-on-report-of-wegovy-tie-up-66e487bb?gaa_at=eafs&gaa_n=AWEtsqfI67ShzxWteXtonRoNzXPQ6KXMT730Ve2KMcyfwMqEDJzaXH6s66aB&gaa_ts=69af63e0&gaa_sig=HTlbjZz6uNe0-LP4MVMGhHwPYdoLkoLsi37Gcdkx_ajOF55xjJbgGzrF6_0os9UUYZe6imWcyD6ua_M4JX5aDw%3D%3D",{"id":120,"title":121,"source":122,"logo":5,"time":78},553384,"Hims & Hers & Novo Nordisk Partner for Ozempic, Wegovy Sales | 2026 - News and Statistics","https://www.indexbox.io/blog/hims-hers-stock-surges-on-novo-nordisk-weight-loss-drug-partnership/",{"id":124,"title":117,"source":125,"logo":5,"time":78},554351,"https://finance.yahoo.com/news/hims-hers-shares-double-report-100600330.html",{"id":127,"title":128,"source":129,"logo":32,"time":78},554349,"Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit","https://www.ksl.com/article/51459220/novo-nordisk-strikes-deal-for-hims-to-sell-wegovy-and-ozempic-drops-lawsuit",{"id":131,"title":117,"source":132,"logo":26,"time":78},553379,"https://www.wsj.com/health/pharma/hims-hers-shares-double-on-report-of-wegovy-tie-up-66e487bb?gaa_at=eafs&gaa_n=AWEtsqeLVqaB77RABcgnL7vjtLdOvKKbsgbDyEbaxkrfaHIDwSxGFPpZLIDR&gaa_ts=69af2b9a&gaa_sig=yjxkHZP6RVMJr4plPTnpHSoUE_z40AjlBt4Rzq1t8TnSNJ1vB_eTqSru1gicixFefE5pifYvC6r23kcCpJPiGA%3D%3D",{"id":134,"title":135,"source":136,"logo":35,"time":78},553378,"Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment","https://www.morningstar.com/stocks/hims-hers-repartnering-with-novo-removes-legal-overhang-reshapes-weight-loss-segment",{"id":138,"title":139,"source":140,"logo":29,"time":78},553377,"Hims & Hers Made a Surprising Concession to End Its GLP‑1 Beef With Novo Nordisk","https://www.inc.com/annabel-burba/hims-hers-made-a-surprising-concession-to-end-its-glp-1-beef-with-novo-nordisk/91313836",{"id":142,"title":143,"source":144,"logo":15,"time":78},554345,"Hims & Hers Health boosted at Citi on Novo Nordisk partnership","https://seekingalpha.com/news/4562501-hims-hers-health-boosted-at-citi-on-novo-nordisk-partnership",{"id":146,"title":147,"source":148,"logo":5,"time":78},554346,"Novo Nordisk deal lets Hims sell Wegovy and Ozempic, drops lawsuit","https://www.usatoday.com/story/money/2026/03/09/ozempic-maker-novo-deal-hims-lawsuit/89070470007/",{"id":150,"title":151,"source":152,"logo":13,"time":78},554347,"Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s","https://thehill.com/policy/healthcare/5775413-novo-nordisk-hims-hers-collaboration/",{"id":154,"title":155,"source":156,"logo":5,"time":78},554348,"Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?","https://finance.yahoo.com/news/hims-hers-stock-challenging-50-194524152.html",{"id":158,"title":159,"source":160,"logo":38,"time":78},553372,"Hims & Hers Health: The Potential Deal With Novo Nordisk Is A Game-Changer (NYSE:HIMS)","https://seekingalpha.com/article/4880015-hims-hers-health-stock-potential-deal-novo-nordisk-game-changer",{"id":162,"title":163,"source":164,"logo":5,"time":78},554341,"Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal","https://finance.yahoo.com/news/stock-market-today-march-9-222501953.html",{"id":166,"title":167,"source":168,"logo":5,"time":78},553371,"Hims & Hers Announces Strategic Shift for US Weight Loss Business","https://finance.yahoo.com/news/hims-hers-announces-strategic-shift-123000312.html",{"id":170,"title":163,"source":171,"logo":41,"time":78},554342,"https://www.fool.com/coverage/stock-market-today/2026/03/09/stock-market-today-march-9-hims-hers-health-soars-on-novo-nordisk-weight-loss-drug-deal/",{"id":173,"title":128,"source":174,"logo":44,"time":78},553370,"https://www.reuters.com/legal/litigation/novo-nordisk-strikes-deal-hims-sell-wegovy-ozempic-drops-lawsuit-2026-03-09/",{"id":176,"title":177,"source":178,"logo":21,"time":78},554343,"Hims & Hers stock skyrockets 40% as Novo Nordisk ends feud, agrees to sell Ozempic and Wegovy on platform","https://www.marketwatch.com/story/hims-hers-stock-rockets-on-reported-end-to-novo-nordisk-weight-loss-drug-dispute-debbfade?gaa_at=eafs&gaa_n=AWEtsqcTv1xmSyUzdGZsVPhrojyXbKFIiRhlv9hHLTxKyebFJApmzUSs7Bbj&gaa_ts=69af63e0&gaa_sig=GvvuKZYUpIaccYr0yIjKDYp4dEiMb2MSh_7PRnVTKsmzYhlWLir9l8NsHiF9VsjKAhxrpIvsfV6ZjeRV3UFpRA%3D%3D",{"id":180,"title":181,"source":182,"logo":5,"time":78},554344,"The era of $199 copycat weight loss drugs is ending — and it could cost patients","https://www.yahoo.com/lifestyle/article/the-era-of-199-copycat-weight-loss-drugs-is-ending--and-it-could-cost-patients-213706107.html",{"id":184,"title":155,"source":185,"logo":39,"time":78},553376,"https://www.barchart.com/story/news/648468/hims-hers-stock-is-challenging-its-50-day-moving-average-should-you-bet-on-a-turnaround-here",{"id":187,"title":188,"source":189,"logo":14,"time":78},553375,"Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud","https://www.bloomberg.com/news/articles/2026-03-09/hims-hers-surges-on-novo-obesity-deal-that-ends-public-feud",{"id":191,"title":177,"source":192,"logo":21,"time":78},553374,"https://www.marketwatch.com/story/hims-hers-stock-rockets-on-reported-end-to-novo-nordisk-weight-loss-drug-dispute-debbfade?gaa_at=eafs&gaa_n=AWEtsqcsKafrmtpUiy4TELsxmMlbQ2UuprrgWvkv5Xbs71L7NnQ-oDaPDDvN&gaa_ts=69af2b9a&gaa_sig=LKo9GdNNEBWLYiGj_b9VB147SxA1vmVUgZt7RGDIrobnAEIE9pvFXG-pkupgqIuRm37TAHuytBfnJ5ee7UOtug%3D%3D",{"id":194,"title":195,"source":196,"logo":33,"time":78},553373,"Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform","https://www.reuters.com/legal/litigation/hims-shares-jump-after-report-novo-nordisk-partnership-that-may-end-legal-feud-2026-03-09/",{"id":198,"title":199,"source":200,"logo":5,"time":78},554340,"Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together","https://www.law360.com/healthcare-authority/digital-health-technology/articles/2450190/novo-hims-hers-make-up-agree-to-sell-glp-1s-together",{"id":202,"title":203,"source":204,"logo":5,"time":78},553369,"Novo Nordisk Strikes Deal for Hims to Sell Wegovy and Ozempic, Drops Lawsuit","https://money.usnews.com/investing/news/articles/2026-03-09/novo-nordisk-strikes-deal-for-hims-to-sell-wegovy-and-ozempic-drops-lawsuit",{"id":206,"title":207,"source":208,"logo":10,"time":78},553368,"What’s Happening With HIMS Stock?","https://www.forbes.com/sites/greatspeculations/2026/03/09/whats-happening-with-hims-stock/",{"id":210,"title":211,"source":212,"logo":16,"time":78},553401,"Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs","https://www.investors.com/news/hims-and-hers-stock-surges-40-deal-sell-novo-nordisk-obesity-drugs/",{"id":214,"title":215,"source":216,"logo":5,"time":78},554339,"Hims & Hers is soaring after a stunning legal reversal","https://rollingout.com/2026/03/09/hims-hers-novo-nordisk-deal-stock-surge/",{"id":218,"title":219,"source":220,"logo":37,"time":78},553367,"Hims shares jump after report of Novo Nordisk partnership that may end legal feud","https://www.msn.com/en-us/money/companies/hims-shares-jump-after-report-of-novo-nordisk-partnership-that-may-end-legal-feud/ar-AA1XPqHG",{"id":222,"title":223,"source":224,"logo":45,"time":78},553400,"Hims & Hers Health will stop selling compound GLP-1 to settle lawsuit","https://www.10tv.com/article/news/nation-world/hims-hers-stop-selling-compound-glp-1-settle-lawsuit-wegovy/507-f40f2c06-47df-4eb4-a641-891030a4bb74",{"id":226,"title":227,"source":228,"logo":40,"time":78},555340,"Novo Nordisk Ends Lawsuit, Collaborates With Hims & Hers to Sell Semaglutide","https://www.medpagetoday.com/endocrinology/obesity/120218",{"id":230,"title":231,"source":232,"logo":42,"time":78},555339,"Hims & Hers will sell real Ozempic in deal with Novo Nordisk","https://qz.com/hims-hers-novo-nordisk-ozempic-wegovy-lawsuit-stock",{"id":234,"title":235,"source":236,"logo":36,"time":78},553399,"Is The Hims/Novo Saga Over? Hims Catapults On A Deal.","https://www.investors.com/news/technology/hims-stock-novo-nordisk-deal-oral-wegovy-glp-1/",{"id":238,"title":239,"source":240,"logo":30,"time":78},555335,"Hims & Hers: Not Selling Yet (NYSE:HIMS)","https://seekingalpha.com/article/4880234-hims-and-hers-not-selling-yet",{"id":242,"title":117,"source":243,"logo":26,"time":78},555412,"https://www.wsj.com/health/pharma/hims-hers-shares-double-on-report-of-wegovy-tie-up-66e487bb?gaa_at=eafs&gaa_n=AWEtsqc_ts9V9p_PLlR6tcColt6U3hsCcMHfREJzSTRzlrWkhig5FphDEBJs&gaa_ts=69af9c0d&gaa_sig=T_Rj_hsUky3P9bk0T44gVNagTHwx3sYpm0GHwn2hrhSTe-z1QWQHyDZTNsImcd-9pFm5Kvh6fk1QbvS2u5ALHQ%3D%3D",{"id":245,"title":177,"source":246,"logo":21,"time":78},555336,"https://www.marketwatch.com/story/hims-hers-stock-rockets-on-reported-end-to-novo-nordisk-weight-loss-drug-dispute-debbfade?gaa_at=eafs&gaa_n=AWEtsqfxKGJvPyulUd0k7TGM5WQ14E6cUBGsQ-n7_WX4qsBQVsqtOm5cTHZu&gaa_ts=69af9c0d&gaa_sig=D5ZhmL05SftTj97SDwvwkd6b_1PKAeQnXXYRgABA4qoHtj5I8kpm1X9dzDBwVXRe75GBlXE-qZ9Ifem0tkVwtw%3D%3D",{"id":248,"title":155,"source":249,"logo":20,"time":78},555337,"https://markets.financialcontent.com/wral/article/barchart-2026-3-9-hims-and-hers-stock-is-challenging-its-50-day-moving-average-should-you-bet-on-a-turnaround-here",{"id":251,"title":252,"source":253,"logo":34,"time":78},555338,"Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?","https://www.fool.com/investing/2026/03/09/hims-hers-health-shares-skyrocket-on-novo-nordisk/",{"id":255,"title":256,"source":257,"logo":31,"time":78},553390,"Novo Nordisk drops lawsuit against Hims & Hers over off-brand weight loss medications, enter collaboration","https://www.pbs.org/newshour/nation/novo-nordisk-drops-lawsuit-against-hims-hers-over-off-brand-weight-loss-medications-enter-collaboration",{"id":259,"title":260,"source":261,"logo":12,"time":78},553394,"Stock Movers: Hims & Hers Health, Live Nation Entertainment, Brown-Forman","https://www.bloomberg.com/news/audio/2026-03-09/stock-movers-hims-hers-live-nation-brown-forman-podcast",{"id":263,"title":264,"source":265,"logo":11,"time":78},553393,"Novo, Hims reach deal to sell GLP-1 drugs together","https://www.biopharmadive.com/news/hims-novo-deal-obesity-drugs-wegovy-ozempic/814160/",{"id":267,"title":268,"source":269,"logo":5,"time":78},553392,"BTIG reiterates Neutral on Hims and Hers stock amid Novo strategy","https://www.investing.com/news/analyst-ratings/btig-reiterates-neutral-on-hims-and-hers-stock-amid-novo-strategy-93CH-4550070",{"id":271,"title":272,"source":273,"logo":24,"time":274},555333,"Novo Nordisk, Hims & Hers settle GLP-1 drug dispute","https://njbiz.com/novo-nordisk-hims-hers-glp1-drug-settlement/","1D AGO",{"id":276,"title":277,"source":278,"logo":46,"time":78},553391,"Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute","https://www.biospace.com/drug-delivery/novo-nordisk-agrees-to-sell-glp-1-drugs-via-hims-hers-ending-dispute",{"id":280,"title":281,"source":282,"logo":5,"time":78},555334,"Hims & Hers Stock Pops 40%: Everything You Need to Know","https://www.aol.com/finance/hims-hers-stock-pops-40-155801034.html",{"id":284,"title":285,"source":286,"logo":19,"time":78},553398,"Hims & Hers makes deal with Novo Nordisk as it shifts obesity strategy","https://www.fiercehealthcare.com/health-tech/hims-hers-makes-deal-novo-nordisk-it-shifts-obesity-strategy",{"id":288,"title":289,"source":290,"logo":5,"time":78},553397,"Hims & Hers stock jumps after Novo Nordisk drops lawsuit","https://finance.yahoo.com/news/hims-hers-stock-jumps-novo-145430771.html",{"id":292,"title":289,"source":293,"logo":5,"time":78},553396,"https://www.upi.com/Top_News/World-News/2026/03/09/novo-nordisk-lawsuit-hims-hers-dropped/5611773067671/",{"id":295,"title":296,"source":297,"logo":5,"time":78},553395,"Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform","https://finance.yahoo.com/news/hims--hers-stock-surges-as-novo-nordisk-says-it-will-distribute-weight-loss-drugs-on-platform-150816824.html",{"id":299,"title":300,"source":301,"logo":23,"time":78},553424,"Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration","https://apnews.com/article/hims-hers-novo-nordisk-wegovy-ozempic-fda-d56b8ad0737be75674bc05ffe488b948",{"id":303,"title":304,"source":305,"logo":18,"time":78},553423,"Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs","https://www.cnbc.com/2026/03/09/novo-nordisk-ends-legal-proceedings-hims-hers-compounded-weight-loss-drugs.html",{"id":307,"title":308,"source":309,"logo":5,"time":78},553389,"Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy","https://www.aol.com/articles/novo-nordisk-drops-lawsuit-over-152301970.html",{"id":311,"title":167,"source":312,"logo":5,"time":78},553422,"https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx",{"id":314,"title":315,"source":316,"logo":5,"time":78},553388,"Telehealth Meets Weight-Loss Boom: Why Hims & Hers Is Surging on Wegovy Partnership News","https://earthtimes.org/telehealth-meets-weight-loss-boom-why-hims-hers-is-surging-on-wegovy-partnership-news/",{"id":318,"title":128,"source":319,"logo":5,"time":78},553421,"https://finance.yahoo.com/news/novo-nordisk-strikes-deal-hims-123637610.html","#b339afff","#b339af4d",1773293455358]